Promising Results For Glivec In CML Continue, FDA Grants Priority Review
High Response Rate of Hairy Cell Leukemia Patients to Immunotoxin Treatment In Phase I
Wilms’ Tumor Survivors At High Risk Of Heart Failure
Cancer Pain Treatment Guide Published By NCCN, ACS
Without Advance Directives, Families Prolong Treatment
Long-Term Estrogen Use May Increase Ovarian Cancer Risk
Natural Substance Blocks Androgen Activity In Vitro
NCI-Approved Clinical Trials Listed For Month Of March
Trending Stories
- Richard Pazdur left FDA to avoid being part of “the destruction of the American medical system”
- In first NCAB director’s report, Anthony Letai focuses on centralized grant review, budget outlook
- Pazdur leaves FDA after 25-year career that shaped the agency’s oncology regulations
BIO calls for the end of “constant turmoil,” urges the administration to “right the ship” - Pediatric cancer five-year survival rate has increased dramatically, AACR says in inaugural Pediatric Cancer Progress Report
- Anthony Letai pledges to ensure stability for extramural and intramural cancer science
- Vinay Prasad to CBER employees: “It is not wise for FDA to further pollute the scientific literature with papers we cannot defend”









